ENTRY       D10756            Mixture   Drug
NAME        Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil;
            Stribild (TN)
PRODUCT     STRIBILD (Gilead Sciences)
COMPONENT   Elvitegravir [DR:D06677], Cobicistat [DR:D09881], Emtricitabine [DR:D01199], Tenofovir disoproxil fumarate [DR:D01982]
CLASS       Antiviral
             DG03107  Anti-HIV agent
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01645  CYP2D6 inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
REMARK      ATC code: J05AR09
            Product: D10756<US>
EFFICACY    Antiviral
  DISEASE   HIV-1 infection [DS:H01563]
COMMENT     Elvitegravir is metabolized by CYP3A.
            Cobicistat is metabolized by CYP3A with some contribution from by CYP2D6 and it is an inhibitor of CYP3A, CYP2D6 and P-glycoprotein (P-gp).
TARGET      HIV-1 reverse transcriptase [KO:K24802]
            HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24802+K24803)  Viral genome structure
            ko03240(K24802+K24803)  Viral replication
            ko03250(K24802+K24803)  Viral life cycle - HIV-1
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]; CYP2D6 [HSA:1565]
INTERACTION CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
            Transporter inhibition: ABCB1 [HSA:5243]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AR Antivirals for treatment of HIV infections, combinations
                 J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
                  D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil &lt;US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Combinations
               Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate
                D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
              DG01633  CYP3A/CYP3A4 substrate
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
              DG02852  CYP3A/CYP3A4 inhibitor
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10756
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10756
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10756
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10756
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10756
             Drug transporters
              D10756
DBLINKS     PubChem: 273220352
///
